Kornimate/medical-research-clean huggingface dataset:
development of validated bruise scale in hnv

Conditions: Bruise, Contusion

Summary: subjects will have a mechanically induced bruise photographed over a period of 11 days to record the healing process. assessors will rate the bruises to develop a bruising scale.

observational study. healthy normal volunteers will come into the clinic and have a bruise induced. the bruised area will be photographed each day through day 11. images will be provided to the validator team to rate on a 0-5 scale of severity. the actual numbers of volunteers will be adjusted to ensure there are at least 15 images for each grade. the clinical site will be provided photography equipment, and study staff will be trained on photography technique to standardize the image quality and resolution across the study. the validator team will review the images and categorize them in to grades 0-5.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin type 1-3 * bmi 25 kg/m2 * self described bruisers * intact skin in the target area, free of markings, blemishes and hair exclusion criteria: * use of recreational drugs, steroids, pain medications, other homeopathic remedies, anticoagulant therapies, antiplatelet therapy * known history of dermal sensitivity, serious illness, hematological abnormality, impaired wound healing * inability to forego application of topical products in the target area * hair removal by laser, wax or chemicals within one week prior to day 1 * avoid tanning beds * active wound or infection in the target area * history of keloids or hypertrophic scarring * history of collagen or vascular disease * history of organ transplant
administration of gv1001 for the treatment of progressive supranuclear palsy who completed study gv1001-psp-cl2-011

Conditions: Progressive Supranuclear Palsy

Summary: the study will be conducted by the sponsor to evaluate twelve-months long-term safety and efficacy of gv1001 (1.12 mg) administered subcutaneously as a treatment for progressive supranuclear palsy(psp). in 75 patients diagnosed with psp richardson(psp-rs) or psp-parkinsonism (psp-p) who completed study gv1001-psp-cl2-011.

in gv1001-psp-cl2-011 study, subjects who were in the trial group (study group 1(gv1001 0.56 mg/day), study group 2(gv1001 1.12 mg/day) is alternately administered high-dose test drug(gv1001 1.12 mg/day) and placebo once a week from ex-visit 1(visit 16, week 26) to ex-visit 5(visit 20, week 30) and high-dose test drugs(gv1001 1.12 mg/day) are administered from ex-visit 6 (visit 21, week 32) to ex-visit 26(visit 41, week 72) every two weeks. in the gv1001-psp-cl2-011 study, subjects who were in the placebo group are administered placebo at ex-visit 1 (visit16, week26), the first visit of the extension study, and ex-visit 2 (visit17, week27) to ex-visit 5 (visit 20, week 30), high-dose test drugs(gv1001 1.12 mg/day) are administered once a week and high-dose test drugs (gv1001 1.12 mg/day) are administered from ex-visit 6 (visit 21, week 32) to ex-visit 26(visit 41, week 72) every two weeks.

Eligibility criteria:
inclusion criteria: * a person who has been registered in the gv1001-psp-cl2-011 clinical trial and has completed administration by week 24 * a patient who accompanied all visits with the subject for the scheduled visit of this clinical trial, has a guardian who can supervise the subject's compliance with the examination and examination procedures conducted at the time of the visit, and provides information on the subject's indications, and whose guardian has agreed in writing to participate in the clinical trial (except where it is unnecessary to accompany the guardian at the discretion of the investigator) * patient and/or representative of the patient who has voluntarily agreed in writing to participate in this clinical trial exclusion criteria: * patients deemed unsuitable by the investigator to participate in this extension study * pregnant or male subjects who do not consent to contraception by medically approved methods (surgical infertility, intrauterine contraceptive devices, fallopian tube ligature, double blocking (combined use of male condoms, female condoms, cervical caps, contraceptive diaphragm and sponges) and 90 days after clinical trial participation however, women who have undergone menopause or surgical infertility procedures (such as vasectomy and difficult conception on both sides) before participating in clinical trials can participate without consent to contraception. * pregnant women or breastfeeding women

Keywords: progressive supranuclear palsy gv1001
out-of-hospital cpap study

Conditions: Acute Cardiogenic Pulmonary Edema

Summary: evaluate efficacy and safety of cpap in a randomised standard treatment controlled study, in out-of-hospital patients with acute cardiogenic pulmonary edema.

acute cardiogenic pulmonary edema is a frequent medical emergency. several studies have shown that continuous positive airway pressure is effective in acute cardiogenic pulmonary edema, through improvement in gas exchange, reduction in intubation rate and a trend towards reduced mortality. cpap is usually obtained with a hermetic nasal or facemask witch has an expiratory valve to maintain a positive pressure at the end of the expiration. with this support, the patient does not receive any assistance with respiration. the available data about cpap concern patients hospitalised in cardiology intensive care units, in resuscitation areas or in emergency departments. we will undertake a controlled prospective randomised trial to investigate whether the early use of cpap would improve oxygenation and survival, as compared with standard medical therapy in patients with acute cardiogenic pulmonary edema. this study will include 124 patients over 18 years of age, suffering of acute cardiogenic pulmonary edema, with a respiratory rate greater than 25 bpm and oxygen saturation less than 90 %. the patients will be include just after the beginning of the episode, in prehospital mobile intensive car unit (samu) and will be all admitted in resuscitation area in a central hospital. they will be randomly assigned to cpap or conventional oxygen therapy. the randomisation sequence is generated by the random numbers table. closed envelopes containing the allocated treatment will be stored in the emergency department and will be opened when the patient is included. oxygen saturation (by pulse-oxymetry), heart rate, respiratory rate, dyspnea, blood pressure will be measured every 15 min during the transport to the intensive care unit and every hour. the blood gazes will be measured at the arrival. the intubation rate, the duration of the hospitalisation and the mortality in the thirty days following initial treatment will be noted.

Eligibility criteria:
inclusion criteria: * patient with supposed acute cardiogenic pulmonary edema, defined as acute dyspnea associated with a past of cardiomyopathy ischemia and physical signs consistent with pulmonary edema. * patient giving written informed consent exclusion criteria: * glasgow score \< 10 * acute myocardial infarction ; ventricular arrhythmia ; pneumothorax ; evidence of pneumonia ; immediate need for intubation ; heart failure or respiratory stop witch requires a reanimation ; cardiogenic shock (systolic blood pressure \< 90 mmhg) * any neurological impairment that would prevent the protocol compliance * participation in another study throughout this one * women pregnant or nursing * vomiting * patient with an history of gastric surgery (\< 8days)

Keywords: pulmonary disease cpo cpap oxygenation out-of-hospital intervention
cost of cancer risk management in women at elevated genetic risk for ovarian cancer who participated on gog-0199

Conditions: Fallopian Tube Carcinoma; Hereditary Breast and Ovarian Cancer Syndrome; Ovarian Carcinoma; Primary Peritoneal Carcinoma

Summary: this research trial collects information about types of treatment and the cost of these procedures in women with elevated genetic risk for ovarian cancer who participated on the gynecology oncology group (gog)-0199 trial. gathering information about women at elevated genetic risk for ovarian cancer may help doctors learn more about risk reduction procedures and the cost of these procedures.

primary objectives: i. to estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of risk-reducing salpingo-oophorectomy (rrso) versus ovarian cancer screening (ocs) for women at elevated genetic risk of ovarian cancer over a five-year period, using data from gog-0199 to model survival. secondary objectives: i. to estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of rrso versus ocs for women at elevated genetic risk of ovarian cancer over a lifetime, using stage-specific cohorts and population-based data to model long-term survival. (exploratory) ii. to use value of information (voi) methodology to set future research priorities aimed at developing evidence-based approaches to the management of women who are at elevated genetic risk of ovarian cancer. (exploratory) outline: outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the gynecologic oncology group (gog)-0199 records and analyzed. cost of each medical intervention is also estimated.

Eligibility criteria:
inclusion criteria: * women who were eligible and evaluable for gog-0199, a prospective, non-randomized, natural history study * data collected from gog-0199 available
pre-habilitation in lung surgery candidates

Conditions: Lung Cancer; Post-Op Complication

Summary: we hypothesize that high intensity respiratory muscle training will improve ventilatory efficiency (ve/vco2 slope) and will be associated with decreased ppc, decreased mortality and better quality of life in lung resection candidates. accordingly, the aim of this study will be to compare rest and exercise ventilation and gas exchange parameters as well as postoperative complications, quality of life and mortality in patients who undergo high intensity respiratory muscle training compared to patients who receive the usual standard of care.

lung resection surgery is the major curative option for lung cancer. therefore, it is alarming that up to 37% of suitable patients are considered inoperable because of lung function impairment and those suitable for operation still carry a significant risk of especially postoperative pulmonary complications (ppc) development and increased mortality. several predictors of postoperative morbidity and mortality have been identified. however, most of the factors are not easily modifiable before surgery. ventilatory efficiency for carbon dioxide (ve/vco2 slope) is an exercise parameter that has been shown to predict respiratory complications and mortality of lung resection candidates and to be superior to peak oxygen uptake (peak vo2). importantly, in contrast to most previously established ppc risk factors, ve/vco2 slope and peak vo2 may be therapeutically improved by physical and/or respiratory muscle training (e.g. by prehabilitation) and may thereby enable preoperative patient optimization. in thoracic surgery patients, trials looking at improvement of exercise capacity and ppc development give conflicting results, probably because of huge heterogeneity in terms of type, intensity and the length of pre-habilitation program. however, it seems that inclusion of only selected patients that may benefit from pre-habilitation (high risk patients), using ve/vco2 slope and not peak vo2 to define the high risk patients and using interventions that could effectively improve ve/vco2 slope (like the inspiratory and expiratory muscle training) is crucial and may be the key to lowering of postoperative pulmonary complications. therefore, we hypothesize that high intensity respiratory muscle training will improve ventilatory efficiency (ve/vco2 slope) and will be associated with decreased ppc, decreased mortality and better quality of life in lung resection candidates.

Eligibility criteria:
inclusion criteria: * ventilatory efficiency (ve/vco2) ≥ 33 exclusion criteria: * contraindication for lung resection (e.g. inoperable tumor)

Keywords: cardiopulmonary exercise testing ve/vco2 petco2
this study is to estimate the time course of pf-04764793 in the blood following dosing by oral inhalation from dry powder inhalers

Conditions: Healthy

Summary: the purpose of this study is to investigate the time course of pf-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 21 and 55 years. * body mass index (bmi) of 17.5 to 30.5 kg/m\^2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * a positive urine drug screen. * history of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males. * pregnant or nursing females.
study of oral enmd-2076 administered to patients with ovarian cancer

Conditions: Ovarian Cancer; Fallopian Cancer; Peritoneal Cancer

Summary: the purpose of this study is to determine whether oral enmd-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. additional sites to be added.


Eligibility criteria:
inclusion criteria: * have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer that is platinum resistant. * have a pre-study echocardiogram or multigated acquisition (muga) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal * greater than or equal to 18 years of age * have clinically acceptable laboratory screening results * have an ecog performance status of 0 or 1 * able to tolerate oral medications exclusion criteria: * have uncontrolled hypertension (systolic blood pressure greater than 150mmhg or diastolic blood pressure greater than 100mmhg); require two or more antihypertensive medications to control hypertension (including ace inhibitors, beta blockers, calcium channel blockers, or diuretics) * have chronic atrial fibrillation or qtc interval corrected for heart rate of greater than 470 msec * have active, acute, or chronic clinically significant infections or bleeding * have persistent 2+ protein by urinalysis or a history of nephrotic syndrome

Keywords: ovarian platinum resistant ovarian cancer
characteristics and outcomes of patients with hematological malignancies

Conditions: Haematologic Neoplasm

Summary: the pattern of hematological malignancies (hms) in developing countries and developed countries differs. among the different types of cancers, leukemia, lymphoma, and multiple myeloma appear to have greatly increased in frequency.

the pattern of hematological malignancies (hms) in developing countries and developed countries differs. among the different types of cancers, leukemia, lymphoma, and multiple myeloma appear to have greatly increased in frequency. these malignancies are induced by genetic damage or mutation in somatic cells, which can result from environmental exposure to chemicals, ionizing radiation, and viral agents. comparison of the incidence of hms across geographic regions and time is complicated by the existence of different disease classification systems, and diagnostic criteria that vary by country, and even between hospitals and cancer registries (crs) within a country. leukemia is a malignant neoplasm of hematopoietic stem cells characterized by diffuse replacement of bone marrow or peripheral blood by neoplastic cells; its etiology is obscure. leukemia typing is based on how quickly the disease develops and progresses. leukemia is either chronic or acute. furthermore, leukemia typing is also based on the type of white blood cell that is affected. there are 4 common types of leukemia: acute myeloid leukemia (aml), acute lymphoblastic leukemia (all), chronic myeloid leukemia (cml), and chronic lymphocytic leukemia (cll). most acute leukemias are classified as lymphoid or myeloid lineages via standard microscopic morphology, cytochemistry, and immunophenotyping. previous studies have shown that there are important differences in the incidence of the various leukemia subtypes according to geography, race/ethnicity, age, and trend pattern, indicating that the subtypes may have different etiological factors and that comprehensive global assessment of leukemia patterns is warranted. lymphomas are a heterogenous group of diseases with differences in epidemiology, histology, and prognosis. the incidence of hodgkin's lymphoma (hl) and nonhodgkin's lymphoma (nhl) is higher among males than females. multiple myeloma (mm) is included in the spectrum of diseases ranging from monoclonal gammopathy of unknown significance (mgus) to plasma cell leukemia. plasma cell proliferation usually results in extensive skeletal destruction, with osteolytic lesions, hypercalcemia, anemia, and occasionally plasma cell infiltration in different organs. excessive production of a monoclonal (m) protein can lead to renal failure, hyperviscosity syndrome, or recurrent bacterial infections.

Eligibility criteria:
inclusion criteria: * adult patients of hematological malignancies (≥18 years) exclusion criteria: * patients who have started diagnosis and treatment for malignancy outside assiut university. * age less than 18 years
water-friendly virtual reality and brief thermal pain

Conditions: Pain, Acute

Summary: using immersive virtual reality as a form of pain distraction during a brief "painful but tolerable" temperature.

this study will use quantitative sensory testing (computer-controlled brief 10 second thermal pain stimuli) in healthy college students. the primary aim is to conduct a randomized, controlled study with healthy volunteers to explore whether interacting with virtual objects in vr via a high tech interactive vr system makes vr significantly more effective/powerful compared to a less immersive passive vr system, vs. no vr, for reducing pain during quantitative sensory testing.

Eligibility criteria:
inclusion criteria: * currently enrolled in a course at the university of washington psychology dept., participating in the uw psychology subject pool * able to read, write and comprehend english * able to complete study measures * willing to follow our uw approved instructions * 18 years of age or older exclusion criteria: * people how have already previously participated in this same study (e.g., last quarter) are not eligible to participate again. * not enrolled in a course at the university of washington psychology dept., participating in the uw psychology subject pool * not be able to read, write and comprehend english * younger than 18 years of age. * not capable of completing measures * not capable of indicating pain intensity, * not capable of filling out study measures, * extreme susceptibility to motion sickness, * seizure history, * unusual sensitivity or lack of sensitivity to pain, * sensitive skin, * sensitive feet, * migraines, * diabetes.

Keywords: pain control
peritoneal cavity conditioning during open surgery.

Conditions: Laparotomy; Thoracotomy

Summary: given the observations in animal models and the available data in the human our hypothesis is that peritoneal cavity conditioning (carbon dioxide with 4% of oxygen and 10% of n2o, 100% humidification at 32°c,) during open surgery, will result in an important decrease in postoperative peritoneal inflammation, postoperative pain, and will restore bowel transit faster.

aim of the trial : rct demonstrating that peritoneal cavity conditioning during open surgery will result in a less postoperative inflammation, less postoperative pain, and shorter time to flatus and transit.

Eligibility criteria:
inclusion criteria : * patients will be stratified and randomised according to the type of surgery * total laparoscopic hysterectomy, * promontofixation * cholecystectomy exclusion criteria : * any pre-existing condition increasing the risk of surgery such as age, pre-existing conditions as clotting disorders, heart or lung impairment etc. * not signed informed consent * known allergic reaction to sprayshield, intercoat of hyalobarrier gel ® or - any bowel lesion requiring a single or double layer suture. (given that for none of the any anti-adhesion barriers safety has been proven following bowel lesions and suture) * any condition that might interfere with inflammatory parameters or pre-existing such as ,pregnancy, immunodeficiency, chronic inflammatory disease as crohn's disease, chronic pain conditions as (peripheral neuropathy, pathology of the vertebral column and osteo-articular disease, any condition causing acute pain e.g. trauma.

Keywords: laparotomy thoracotomy peritoneal conditioning humidification temperature control
efficacy of caffeine injection as an adjuvant to opioid therapy in cancer pain

Conditions: Cancer; Pain

Summary: pain is a most common symptom and it has a high impact on quality of life in cancer patients. many cancer patients have received opioid therapy, but also many of them have suffered from side effects of opioids. drowsiness and confusion are common side effects of opioids. caffeine is a well known psychostimulant,and it is widely used as an analgesics. thus, the investigators aimed to prove the efficacy of intravenous caffeine administration as an adjuvant analgesics to opioids. at the same time, the investigators tried to find that the side effects of opioids could be ameliorated by caffeine.

previous studies on cancer pain lacked assessment of quality of life. and most of previous studies on cancer pain did not give attention to symptoms accompanied with pain. we include such variables as outcome measures, and aimed to evaluate the efficacy and the safety of intravenous caffeine in advanced cancer inpatients.

Eligibility criteria:
inclusion criteria: * advanced (stage iv) cancer inpatients * adults aged over 18 years * patients who have received opioid therapy and whose pain scales are under 6 (by numeric rating scale) * patients who do not take caffeine beverage 48 hours before study period * volunteers who provided written informed consent exclusion criteria: * sensitivity (palpitation,headache,irritability,insomnia) to caffeine * uncontrolled hypertension and/or heart disease * liver failure (alanine aminotransferase \>= 100 iu/l) * kidney failure (serum creatinine \>= 2.0 mg/dl) * patients taken theophylline * gastroesophageal reflux disease * chronic glaucoma * cognitive impairment * progressive pain over 7 (by numeric rating scale)

Keywords: pain cancer patients caffeine adjuvant analgesics sedation confusion quality of life fatigue